Reconstructing cerebral lymphatic clearance: an emerging target in the Alzheimer's disease therapeutic pipeline [0.03%]
重建大脑淋巴清除系统：阿尔茨海默病治疗领域的新靶点
Jiheng Zhang,Jiren Zhang,Jian Ding et al.
Jiheng Zhang et al.
Neurotoxic protein accumulation is widely recognized as a key feature of Alzheimer's disease (AD), and increasing evidence indicates that impaired brain clearance associated with dysfunction of the meningeal lymphatic and glymphatic may con...
Speech-based digital cognitive assessment for clinical trials: Detecting cognitive impairment stages and AD biomarker relations across European cohorts [0.03%]
基于语音的数字认知临床试验评估：在欧洲队列中检测认知障碍阶段和阿尔茨海默病生物标志物之间的关系
Alexandra König,Johannes Tröger,Elisa Mallick et al.
Alexandra König et al.
Introduction: Early detection of Alzheimer's disease (AD) is critical for timely intervention as disease-modifying treatments emerge. Speech-based digital biomarkers offer scalable options for remotely capturing speech-de...
Altered amygdala structural connectivity and relations to social cognition in frontotemporal dementia [0.03%]
额颞叶痴呆患者杏仁核结构连接的改变及其与社会认知的关系
Mengjie Huang,Marshall A Dalton,Sophie Matis et al.
Mengjie Huang et al.
Introduction: The amygdala is critical for social cognition and undergoes profound damage in frontotemporal dementia (FTD). While its atrophy is well documented, changes in its structural connectivity and their behavioral...
Physical activity, aerobic fitness, and AD blood biomarkers: The IGNITE study [0.03%]
身体活动，有氧适能与阿尔茨海默病血液生物标志物的相关性：来自IGNITE研究的证据
Lauren E Oberlin,Patricio Solis-Urra,Kelsey R Sewell et al.
Lauren E Oberlin et al.
Introduction: Physical activity (PA) and cardiorespiratory fitness (CRF) are associated with reduced risk of cognitive decline and dementia, yet their relationships with dementia-related pathophysiology remain unclear. In...
Remote, unsupervised assessment of cognitive impairment and decline in Alzheimer's disease using the Cogstate Brief Battery in ADNI-3 [0.03%]
利用ADNI-3远程无监督评估阿尔茨海默病患者认知障碍及衰退的COGSTATE简易量表研究
Paul Maruff,Bruce Albala,Danielle Harvey et al.
Paul Maruff et al.
Introduction: Remote neuropsychological testing can monitor brain health in individuals with or at risk of Alzheimer's disease (AD). We evaluated acceptability and validity of the Cogstate Brief Battery (CBB) for remote a...
A sensorimotor function construct to assess mild cognitive impairment risk [0.03%]
一种用于评估轻度认知障碍风险的感觉运动功能结构
Amal A Wanigatunga,Hang Wang,Di Huang et al.
Amal A Wanigatunga et al.
Introduction: Identifying precursors to mild cognitive impairment (MCI)-the transitional stage between unimpaired cognition and dementia-is a public health priority. While sensory and motor impairments are each linked to ...
Melina Stark,Michael Wagner,Elizabeth Kuhn et al.
Melina Stark et al.
Introduction: Subtle symptoms, like subjective cognitive decline (SCD) and minor neuropsychological deficits (MNPD), can improve the risk stratification in preclinical Alzheimer´s disease (AD) but their importance is ins...
Mandarin speech-based early detection of SCD: a feature-fusion residual network method [0.03%]
基于普通话的说话人边界检测及说话人变更检测：一种特征融合残差网络方法
Zhou Liu,Chao Che,Guimei He et al.
Zhou Liu et al.
Introduction: Alzheimer's disease (AD) poses a global health challenge. Early intervention during the stage of subjective cognitive decline (SCD) - a potential window for delaying disease progression - is crucial. This st...
Metabolomic ageing (MileAge) in mid-life predicts incident vascular, unspecified and all-cause dementia [0.03%]
其中年代谢组老化（MileAge）可预测血管性、原因未明及全因痴呆症的发病风险
Julian Mutz,Lachlan Gilchrist,Oliver Pain et al.
Julian Mutz et al.
Introduction: Identifying individuals at risk of dementia is essential for prevention and targeted disease-modifying strategies. We investigated whether mid-life metabolomic ageing is associated with incident dementia and...
Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysis [0.03%]
阿尔茨海默病新兴疾病修饰疗法在174个国家的价值定价：成本效益和阈值分析
Men Thi Hoang,James G Kahn,Sanjib Saha et al.
Men Thi Hoang et al.
Introduction: Countries have varying, limited healthcare budgets for emerging disease-modifying therapies. Cost-effectiveness analysis, combined with country-level cost-effectiveness thresholds, can be used to estimate va...